Tms (4891) · FactRestated

Single Pharmaceutical Development Segment

First written in FY2023-Q3. 8 of 9 entries say "Restated". Latest entry: FY2027-H1.

9entries

4years

0from disclosures

Share on X

How it moved

Same theme, other companies

Single-segment structure focused on drug discoveryA theme 6 companies write about · 0 as a headwind · 1 as a tailwind

4 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Full recordFilings, disclosures and news, newest first

FY2027-H1RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2026-H1RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2025RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2025-H1RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2025-Q1RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company reiterated that it operates solely in the pharmaceutical development segment.
FY2024-Q2RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2024-Q1RestatedAnnual report
「The Company operates in a single segment, pharmaceutical development, and therefore omits segment operating results.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2023RestatedAnnual report
「Because the Company operates in a single segment, pharmaceutical development, whose business purpose is the research, development, manufacture and sale of pharmaceuticals, segment information is omitted.」
The Company continues to report that it operates solely in the pharmaceutical development segment.
FY2023-Q3First statedAnnual report
「Because the Company operates in a single segment, pharmaceutical development, segment operating results are omitted.」
The Company operates solely in the pharmaceutical development segment.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Tms yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.